Pain News and Research

Latest Pain News and Research

A common antibiotic used to treat arthritis and acne shows promise for limiting the severity of spinal cord and brain injuries

When a fall, car crash, bullet, or knife crushes or cuts a spinal cord, the injury does not stop there. Rather, tissues continue to discharge toxic chemicals for hours, even days and weeks. These chemicals kill and disable nerve cells some distance away from the core injury, compounding the damage and making rehabilitation more difficult or impossible.

26 Mar 2004

Growth factor protein succeeds in growing new coronary arteries

Three patients of the UC Heart & Vascular Center have grown new coronary artery branches to increase blood flow to the heart after receiving a new growth factor protein (FGF1) in November 2003. All three patients showed improved blood flow to the heart twelve weeks following the injection.

26 Mar 2004

Alfuzosin, new treatment for Acute Urinary Retention

The results of the ALFAUR (ALFuzosin in Acute Urinary Retention) study, announced today at the XIXth European Association of Urology (EAU) Congress in Vienna, Austria, indicate that the uroselective alpha1-blocker alfuzosin 10 mg once daily (OD) may have a beneficial effect in the management of male patients suffering from acute urinary retention (AUR), a sudden inability to pass urine that results in a painful distension of the bladder, requires immediate management with urethral catheterization and could necessitate surgical intervention.

25 Mar 2004

Approval for FOSRENOL (lanthanum carbonate), which controls phosphate levels in renal dialysis patients

Sweden's MPA has today granted the first regulatory approval in the world for FOSRENOL (lanthanum carbonate), a non-calcium, non-aluminium phosphate binding medicine developed to control phosphate levels in renal dialysis patients. Sweden will now become the Reference Member State in the EU Mutual Recognition Procedure for FOSRENOL, and this is the first step in securing marketing approval throughout Europe. A submission has also been made by Shire to gain marketing approval for FOSRENOL in the United States.

25 Mar 2004

Risk of kidney stones increases higher if overweight

Researchers at UT Southwestern Medical Center at Dallas have found that the more overweight a person is the more at risk he or she is for forming uric acid kidney stones.

22 Mar 2004

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.

22 Mar 2004

The placebo effect, study suggest pain management is possible

A Columbia professor has uncovered fresh evidence of the existence of the often-debated placebo effect. Even the professor himself, Tor D. Wager, of the Department of Psychology, was surprised by his team's findings. The study showed that the human brain processes pain differently when people believe that they have been given a pain-relieving skin cream. Wager, lead author of the study, defines "placebo" as a treatment that has no direct pharmacological effect and that may influence one's experience and physiology through one's beliefs.

22 Mar 2004

New Treatment for Chronic Head Pain

Dr. Levy pioneered a procedure known as supraorbital nerve stimulation or SOS, in which neurotransmitters are implanted into the forehead to block head pain. Tiny wires are burrowed under the skin until the precise location of pain is marked by a tingling response to electrical charge. The wires are kept in place for a week, and if pain is lessened and the patient is comfortable with the technology, neurotransmitters are surgically implanted under local anesthesia. The patient is able to control pain relief by manually adjusting the level of electrical stimulation through a hand held device.

22 Mar 2004

Metal-on-metal disc, effective alternative to spinal fusion

The neck and arm pain caused by degenerative cervical (neck) disc disease may be eliminated by replacing the problem disc with a metal-on-metal artificial disc, according to the results of a study presented at the annual meeting of the American Association of Neurological Surgeons/CNS Section on Disorders of the Spine & Peripheral Nerves.

22 Mar 2004

New pill for post-traumatic stress disorder

Every day, people suffer traumatic experiences that scar their minds. Combat, rape, bombings, burns, beatings, and horrific car accidents haunt them with memories impossible to suppress. Such day- and nightmares are part of a problem known as post-traumatic stress disorder, or PTSD.

22 Mar 2004

Atrix Signs Feasibility Agreement for Development of Two New Compounds

Atrix Laboratories, Inc. has announced today that the company has signed a limited feasibility agreement with Aventis SA (NYSE: AVE) to begin preliminary research on two proprietary Aventis compounds formulated in Atrix's delivery technology, Atrigel®. The current agreement is specific for these compounds in an undisclosed therapeutic area.

22 Mar 2004

Patch for post-surgical pain

A patch that delivers pain medication through the skin is just as effective and more convenient than medication delivered by an intravenous pump for post-surgical pain, according to a new study.

22 Mar 2004

New optical glucose sensor could mean help for diabetics

Researchers at the University of California, Santa Cruz, have developed a novel optical glucose sensor that could be used to provide continuous monitoring of glucose levels in diabetics and hospitalized patients. Recently published studies showed that the sensor detects glucose under physiological conditions, giving a reversible fluorescent signal that changes intensity in response to changes in the concentration of glucose.

22 Mar 2004